Transfusional Iron Overload

• FDA approval · 2023-10-16
  FDA Approved: DEFERASIROX — Original Application (NorthStar Rx LLC)

  FDA approves NorthStar Rx LLC's original generic application for deferasirox, a once-daily oral iron chelator for reducing chronic iron over…

• FDA approval · 2023-04-28
  FDA Approved: DEFERASIROX ORAL GRANULES — Supplemental Application (EPIC PHARMA, LLC)

  The FDA approved a supplemental application to authorize Deferasirox Oral Granules (DEFERASIROX) from Epic Pharma, LLC, for the treatment of…

• FDA approval · 2022-09-23
  FDA Approved: DEFERASIROX — Original Application (Teva Pharmaceuticals, Inc.)

  FDA approved Teva's Deferasirox as an original generic application, enabling broader access to this iron chelation therapy for patients with…

• FDA approval · 2022-02-23
  FDA Approved: DEFERASIROX — Original Application (Cipla USA Inc.)

  FDA approves a generic version of deferasirox (Cipla) under an original ANDA application.

• FDA approval · 2020-06-16
  FDA Approved: DEFERASIROX — Original Application (Dr. Reddy's Laboratories Inc)

  FDA approves Dr. Reddy's Laboratories' deferasirox generic under ANDA210945 for the treatment of chronic iron overload due to blood transfus…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2012-06-20
  FDA Approved: DEFEROXAMINE — Supplemental Application (Fresenius Kabi USA, LLC)

  FDA approved a supplemental application for Deferoxamine Mesylate (Deferoxamine) from Fresenius Kabi USA, LLC.

• FDA approval · 2007-04-20
  FDA Approved: EXJADE — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA approved a supplemental application for EXJADE (deferasirox) submitted by Novartis Pharmaceuticals Corporation, resulting in an approved…